These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17337351)

  • 1. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy.
    Berthelot JM; Varin S; Cormier G; Tortellier L; Guillot P; Glemarec J; Maugars Y
    Joint Bone Spine; 2007 Mar; 74(2):144-7. PubMed ID: 17337351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis.
    Wada T; Son Y; Ozaki Y; Nomura S; Iida H
    Mod Rheumatol; 2012 Nov; 22(6):824-30. PubMed ID: 22302136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
    van der Heijde D; Klareskog L; Rodriguez-Valverde V; Codreanu C; Bolosiu H; Melo-Gomes J; Tornero-Molina J; Wajdula J; Pedersen R; Fatenejad S;
    Arthritis Rheum; 2006 Apr; 54(4):1063-74. PubMed ID: 16572441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
    Weinblatt ME; Bathon JM; Kremer JM; Fleischmann RM; Schiff MH; Martin RW; Baumgartner SW; Park GS; Mancini EL; Genovese MC
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):373-82. PubMed ID: 20957659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
    Genovese MC; Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Cannon GW; Spencer-Green G; Finck BK
    Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
    Combe B; Codreanu C; Fiocco U; Gaubitz M; Geusens PP; Kvien TK; Pavelka K; Sambrook PN; Smolen JS; Khandker R; Singh A; Wajdula J; Fatenejad S;
    Ann Rheum Dis; 2009 Jul; 68(7):1146-52. PubMed ID: 18794178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
    Moreland LW; Schiff MH; Baumgartner SW; Tindall EA; Fleischmann RM; Bulpitt KJ; Weaver AL; Keystone EC; Furst DE; Mease PJ; Ruderman EM; Horwitz DA; Arkfeld DG; Garrison L; Burge DJ; Blosch CM; Lange ML; McDonnell ND; Weinblatt ME
    Ann Intern Med; 1999 Mar; 130(6):478-86. PubMed ID: 10075615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Martin Mola E; Pedersen R; Robertson D; Chang D; Koenig A; Freundlich B;
    Ann Rheum Dis; 2009 Jul; 68(7):1113-8. PubMed ID: 18718986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab.
    Matsuno H
    Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.